Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-20
2006-06-20
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S011400, C530S317000, C530S322000, C530S323000, C530S324000, C530S402000
Reexamination Certificate
active
07064105
ABSTRACT:
The present invention relates to tamandarin and didemnin analogs which have a deoxo-proline residue or a dehydro-proline residue in their structure. These analogs are useful as anti-cancer agents and for other purposes. Methods of making these analogs and methods of using them as inhibitors of protein synthesis, cell growth, and tumorigenesis and as enhancers of apoptosis are also provided.
REFERENCES:
patent: 4160452 (1979-07-01), Theeuwes
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4493796 (1985-01-01), Rinehart, Jr.
patent: 4782135 (1988-11-01), Rinehart, Jr.
patent: 5137870 (1992-08-01), Rinehart
patent: 5504189 (1996-04-01), Emling et al.
patent: 2003/0104991 (2003-06-01), Joullie et al.
patent: WO 98/17275 (1998-04-01), None
patent: WO 98/17302 (1998-04-01), None
patent: WO 02/02596 (2002-01-01), None
Grubb et al., Biochem. Biophys. Res. Commun., vol. 215, No. 3, pp. 1130-1136, Oct. 1995.
Pfizenmayer et al., Bioorg. Med. Chem. Lett., vol. 8, pp. 3653-3656, 1998.
Liang et al., J. Am. Chem. Soc., vol. 123, pp. 4469-4474, 2001.
Abdel-Magid et al., 1990, Synlett. 537-539.
Abdel-Magid et al., 1990, Tetrahedron Lett. 31:5595-5598.
Depenbrock et al., 1998, Brit. J. of Cancer 78(6): 739-744.
Ewing et al., 1986, Tetrahedron 42:5863-5868.
Ewing et al., 1989, Tetrahedron Lett. 30:3757-3760.
Ewing, W.R., 1988, Ph.D. Dissertation, University of Pennsylvania, Philadelphia PA.
Green and Wutz, 1999,Protecting Groups in Organic Synthesis, Wiley, New York.
Grubb et al., 1995, Biochem. Biophys, Res. Commun. 215:1130-1136 (Abstract only).
Harris et al., 1987, Tetrahedron Lett. 28:2837-2840.
Harris et al., 1988, Tetrahedron 44:3489-3500.
Johnson et al., 1996, FEBS Lett. 383:1-5.
Johnson et al., 1999, Immunol. Cell Biol. 77:242-248.
Johnson et al., 1999, J. Cell. Biochem. 72:269-278.
Li et al., 1990, J. Am. Chem. Soc. 112:7659-7672.
Li et al., 1992, Studies in Natural Products Chemistry, 10:241-302.
Liang et al., 1999, Org. Lett. 1: 1319-1322.
Mayer et al., 1994, J. Org. Chem. 59:5192-5205.
Mayer et al., 1994, Tetrahedron: Asymmetry 5:519-522.
Pfizenmayer et al., 1998, Bioorg. Med. Chem. Lett., 8:3653-3656 (Abstract only).
Sakai et al., 1996, J. Med. Chem. 39:2819-2834.
Schumacher et al., 1998, Tetrahedron: Asymmetry 9:47-53.
Wipf, 1995, Chem. Rev. 95:2115-2134.
Campbell et al., 1998, Brit. J. of Cancer, 78(6):739-744.
Grubb et al., 1995 Biochem. Biophys. Res. Commun., 215:1130-1136.
Pfizenmayer et al., 1998, Bioorg. Med. Chem. Lett., 8:3653-3656.
Veroort, H., et al., “Tamandarins A and B: New Cytotoxic Depsipeptides from a Brazilian Ascidian of the Family Didemnidae,” J. Org. Chem. 65:782-792, American Chemical Society (2000).
Joullie, M. M., et al., “Total Synthesis of (-)-Tamandarin B,” Tetrahedron Letters 41:9373-9376 Elsevier Science Ltd. (2000).
Liang, B., et al., “Total Synthesis of [(2S)-Hiv2]Didemnin M,” J. Org. Chem. 65:4762-4765, American Chemical Society (2000).
Crews, C. M., et al., “Didemnin Binds to the Protein Palmitoyl Thioesterase Responsible for Infantile Neuronal Ceroid Lipofuscinosis,” Proc. Natl. Acad. Sci. USA 93:4316-4319 Natl. Acad. Sci. (1996).
Supplementary Partial European Search Report, Application No. Ep 01924886.3-2117-US0111607, Jul. 12, 2004.
Ahuja, D., et al., “Inhibition of Protein Synthesis by Didemnin B: How EF-1α Mediates Inhibition of Translocation,”Biochemistry39:4339-4346, American Chemical Society (Apr. 2000).
Ding, X., et al., “Structure-Activity Relationships of Side-Chain Modified Didemnins,”Bioorg. Med. Chem. Lett.11:231-234, Pergamon Press (Jan. 2001).
Joullié, M.M., et al., “Chemical Defense in Ascidians of theDidemnidaeFamily,”Bioconjugate Chem.14:30-37, American Chemical Society (Jan.-Feb. 2003).
Liang, B., et al., “Total Syntheses and Biological Investigations of Tamandarins A and B and Tamandarin A Analogs,”J. Am. Chem. Soc.123:4469-4474, American Chemical Society (May 2001).
Mayer, S., et al., “Synthetic Routes to a Constrained Ring Analog of Didemnin B,”J. Org. Chem.61:1655-1664, Ammerican Chemical Society (1996).
Mayer, S., et al., “The Cyclic Depsipeptide Backbone of the Dideminins,”Acta Cryst.C51:1609-1614, Blackwell Publishing (1995).
Pfizenmayer, A.J., et al., “Synthesis and Biological Activities of [N-MeLeu5] Didemnin B,”Biog. Med. Chem. Lett. 6:2713-2716, Pergamon Press (1996).
Pfizenmayer, A.J., et al., “Synthesis and Biological Activities of [N-MeLeu5]- and [N-MePhe5]- Didemnin B,”Tetrahedron55:313-334, Pergamon Press (Jan. 1999).
Portonovo, P., et al., “First Total Synthesis of a Fluorescent Didemnin,”Tetrahedron56:3687-3690, Pergamon Press (Jun. 2000).
Ramanjulu, J.M., et al., “Synthetic Studies of a Didemnin B Analog Based on a 2,3-Diamino Sugar Scaffolding,”Journal of the Chinese Chemical Society48:1-4, The Chemical Society (Taipei) (2001).
Ramanjulu, J.M., et al., “Syntheses of Acyclic Analogs of Didemnin B,”Synthetic Communications27:3259-3272, Marcel Dekker, Inc. (1997).
Ramanjulu, J.M., et al., “Synthesis of a Reduced Ring Analog of Didemnin B,”J. Org. Chem.62:4961-4969, American Chemical Society (1997).
Ramanjulu, J.M., et al., “Analogs of the β-Turn of the Cyclodepsipeptide Didemnin B,”Tetrahedron Letters37:311-314, Pergamon Press (1996).
Ramanjulu, J.M., et al., “A Facile Synthesis of Benzyl 2-Amino-3-Azido-2-O-p-Methoxybenzyl-6-O-Benzyl-2,3-Dideoxy-α-D-Glucopyranoside: A Key Intermediate in the Formation of a Didemnin B Analog,”J. Carbohydrate Chemistry15:371-381, Marcel Dekker, Inc. (1996).
Tarver, J.E., et al., “Total Syntheses of Conformationally Constrained Didemnin B Analogues. Replacements ofN, O-Dimethyltyrosine with L-1,2,3,4-Tetrahydroisoquinoline and L-1,2,3,4-Tetrahydro-7-methoxyusiquinoline,”J. Org. Chem.66:7575-7587, American Chemical Society (Nov. 2001).
Vera, M.D., et al., “Synthesis and Biological Evaluation of Dldemnin Photoaffinity Analogues,”Biorg. Med. Chem. Lett.11:1871-1874, Pergamon Press (Jul. 2001).
Vera, M.D., et al., “Natural Products as Probes of Cell Biology: 20 Years of Didemnin Research,”Medicinal Research Reviews22:102-145, John Wiley & Sons, Inc. (Mar. 2002).
Vera, M.D., et al., “[Lys3] Didemnins as Potential Affinity Ligands,”Biorg. Med. Chem. Lett. 11:13-16, Pergamon Press (Jan. 2001).
Xiao, D., et al., “Total Synthesis of a Conformationally Constrained Didemnin B,”J. Org. Chem. 66:2734-2742, American Chemical Society (Apr. 2001).
STNEasy/CAplus English language abstract of document FP1, ES2102322A1, Accession No. 1998:169709.
Jou, G., et al ., “Total Synthesis of Dehydrodidemnin B. Use of Uronium and Phosphonium Salt Coupling Reagents in Peptide Synthesis in Solution, ”J. Org. Chem.62:354-366, American Chemical Society (1997).
Ding Xiaobin
Joullie Madeleine M.
Liang Bo
Mohamed Abdel A.
Sterne Kessler Goldstein & Fox P.L.L.C.
The Trustees of the University of Pennsylvania
Weber Jon
LandOfFree
Deoxo-proline-containing tamandarin and didemnin analogs,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Deoxo-proline-containing tamandarin and didemnin analogs,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Deoxo-proline-containing tamandarin and didemnin analogs,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3626670